CDK4 and breast carcinoma: In patients with isolated resected invasive locoregional recurrence of ER-positive/HER2-negative breast cancer, the POLAR trial is currently being conducted to determine the effectiveness of the addition of palbociclib (a CDK-4/6 inhibitor) to adjuvant endocrine therapy versus endocrine therapy alone.